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Abstract
Background: Novel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported
outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS),
acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). The objective of the current study
was to select supplemental items to add to the European Organization for Research and Treatment of Cancer
(EORTC) Quality of Life-Core 30 (QLQ-C30) to ensure content coverage of all important clinical concepts in patients
with higher-risk (HR) MDS, low-blast count (LB) AML, and CMML, thus, improving the instrument’s ability to detect
clinically meaningful treatment benefit for this context of use.
Methods: Our mixed methods approach comprised literature review, clinician consultation (n = 3), and qualitative
and quantitative analysis of two stages of patient interview data (n = 14, n = 18) to select library bank items to
supplement a generic cancer PRO, the EORTC QLQ-C30.
Results: Unique symptom (n = 54) and impact (n = 72) concepts were organized into conceptual frameworks of
treatment benefit, compared with EORTC QLQ-C30 items and conceptual gaps identified. Supplemental items (n = 13)
addressing those gaps were selected from the EORTC Item Library and tested with patients. Supplemental item
endorsement frequencies met World Health Organization Quality of Life criteria, suggesting good targeting and
relevance for this sample. However, three supplemental items were confirmed as problematic based upon cognitive
debriefing results, and expert clinical consultations. Ultimately, 10 supplemental items (n = 7 symptom; n = 3 impact)
were selected for the MDS/AML/CMML context.
Conclusion: Supplemental items were selected to enhance the conceptual coverage of the EORTC QLQ-C30 in the
areas of fatigue, shortness of breath, and functioning.
Keywords: Patient-reported outcomes, Quality of life, Myelodysplastic syndromes, Acute myeloid leukemia, Chronic
myelomonocytic leukemia
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Introduction
Myelodysplastic syndromes (MDS), acute myeloid
leukemia (AML), and chronic myelomonocytic leukemia
(CMML) are rare hematological stem cell disorders, associ-
ated with anemia, neutropenia, and/or thrombocytopenia,
and lead to a variety of symptom and functional impacts.
MDS patients fall into five distinct risk categories with an
increased likelihood of progressing to AML in the
higher-risk (HR) categories [1]. Treatment options for pa-
tients with HR MDS include hypomethylating agents, clin-
ical trial treatments, and stem cell transplant [2].
For low-blast count (LB) AML (which was previously con-
sidered refractory anemia with excess blasts in transform-
ation [RAEB-T] and included in the spectrum of HR
MDS), treatment strategies include intensive chemother-
apy, stem cell transplant, low-intensity chemotherapy, and
supportive care [3]. Recommended therapies for CMML
generally follow the same guidelines as for higher-risk
MDS and AML [2, 3]. Stem cell transplantation is the only
potentially curative treatment, but only a small percentage
of patients are eligible due to advanced age and co-morbid
medical conditions.
Clinicians, researchers, payers, regulatory, and health
technology assessment agencies increasingly recognize
that patient-reported outcome (PRO) instruments are
critical to clinical trials for evaluating the benefits of
new treatments on health-related quality of life
(HRQOL) and when making treatment decisions [4–7].
However, measuring HRQOL in rare diseases can be
challenging, as widely used generic PRO instruments
may lack the sensitivity required to demonstrate clinical
change brought about by new therapies [8, 9]. A recent
Food and Drug Administration (FDA) review of a new
cancer treatment [10] may offer a pragmatic solution:
the use of existing legacy cancer-specific PRO instru-
ments in conjunction with additional items that are
deemed more relevant and important to the specific and
current context of use.
When faced with the challenge of measuring the pa-
tient experience in the context of MDS, AML, and
CMML, we determined that the European Organization
for Research and Treatment of Cancer (EORTC) Quality
of Life-Core 30 (QLQ-C30), a widely used legacy
cancer-specific HRQOL PRO instrument [11], offered
promising potential. The EORTC QLQ-C30 has been
used in over 3000 studies and has supported labeling
claims in the United States (US) and Europe [12, 13].
The EORTC’s Quality of Life Group now offers an Item
Library where researchers can select additional items to
be used with core questionnaires and disease-specific
modules [14]. The Item Library comprises 953 unique
items and 67 questionnaires (with some translated in
over 100 languages [15]), with conceptually defined
scales separating symptoms and impacts. In this study, we
developed a pragmatic PRO strategy for supplementing
the EORTC QLQ-C30 with the most appropriate add-
itional items to specifically measure treatment benefit for
patients with HR MDS, LB AML, and CMML, driven pri-
marily by insights gathered from patients.
Materials and methods
We used a mixed methods approach [16], which in-
cluded literature review, clinician consultation, qualita-
tive patient interviews, and qualitative and quantitative
analysis of patient interview data. This involved the syn-
thesis of qualitative and quantitative data to identify,
define, and operationalize PRO instruments as measures
of a given concept of interest in a specific context of use.
There were two stages: 1) identification of supplemental
symptom and impact items; and 2) supplemental item
evaluation and finalization. An overview of the study
process is provided in Fig. 1.
Stage 1: supplemental item identification
Literature review
We performed a literature review of patient-centered,
qualitative studies in MDS and AML published between
January 2000 and July 2016 to gain an initial understand-
ing of disease- and treatment-related symptoms and im-
pacts. Patient-identified symptom and impact concepts
in MDS and AML were extracted from these studies,
compiled, and organized into hypothesized conceptual
frameworks of treatment benefit [17–19].
Clinician consultation
Three clinicians experienced in treating hematological
disorders were individually consulted to gather add-
itional information on the signs, symptoms, impacts,
and treatment benefits/risks of MDS, AML and CMML.
Clinicians also reviewed the symptoms, impacts, and
hypothesized conceptualizations generated from the lit-
erature review data and provided suggestions for revising
the preliminary frameworks.
Stage 1 patient interviews
Study sample and interview conduct After Independ-
ent Review Board (IRB) approval of the study protocol
(Quorum Review IRB, reference #32211/1), patients
were recruited through one of two sources: 1) advertise-
ments posted by the MDS Foundation, Inc. on their pa-
tient message board, and 2) physician referrals from
three US-based clinical offices. Participating patients
provided written informed consent. Eligible patients
were ≥ 18 years of age; spoke, read, and understood
English; had a diagnosis of HR MDS, LB count AML, or
CMML; and had an Eastern Cooperative Oncology
Group status of 0–2 [20, 21]. Patients were excluded if
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they had received an allogenic stem cell transplant or in-
tensive chemotherapy. All one-on-one interviews lasted
approximately one hour, were conducted by telephone,
audio-recorded, and transcribed.
Concept elicitation, cognitive debriefing, and
qualitative data collection Open-ended, semi-structured
concept elicitation interviews were performed to better
understand the patients’ experience of both the symp-
toms and impacts of their disease. Patients were
debriefed to assess their understanding of the items in
the EORTC QLQ-C30. A “think aloud” process was used
to confirm item relevance and determine whether the
patients interpreted the items and response options in
the manner intended [22]. Item responses were collected
to enable quantitative analysis of EORTC QLQ-C30 data
in this patient population.
Qualitative analysis Concept elicitation transcripts
were analyzed thematically [23, 24] using detailed line-
by-line coding [25] to examine, compare, and develop
treatment benefit concepts using ATLAS.ti software
[26]. Conceptual saturation was assessed by ordering in-
terviews chronologically, then grouping interviews into
quantiles and comparing concepts emerging by each se-
quential quantile to assess whether saturation was
reached (i.e., no new concepts emerged). Stage 1 symp-
tom and impact concepts were added to the concepts
identified through literature review and clinician con-
sultation and data were used to revise the emerging con-
ceptual frameworks of treatment benefit. Cognitive
debriefing analysis for EORTC QLQ-30 items was con-
ducted using a coding framework to organize and cata-
logue patient interpretation, assessment of relevance,
and responses to the core instrument.
Quantitative analysis Item-level endorsement frequency
analysis was performed to describe the distribution of
responses to the items using SPSS 24.0 software. The
World Health Organization Quality of Life (WHOQOL)
criteria were used for interpreting the results (maximum
criterion of < 80% for endorsement frequencies; mini-
mum criterion of > 10% for aggregate endorsement
frequencies; in other words the minimum criterion for
the sum of two adjacent categories [27]).
Gap analysis and supplemental item identification
The symptoms and impacts identified from the literature
review, clinician consultation, and Stage 1 patient inter-
views were compared with the EORTC QLQ-C30 items
to identify measurement gaps and to guide the selection
of supplemental items from the EORTC Item Library to
address the instrument’s conceptual gaps. The following
criteria guided supplemental item selection:
 Concept was NOT primarily considered a side effect
of treatment
 Concept was strongly endorsed by patients or
considered a core symptom/impact by clinicians
 Concept had potential to demonstrate treatment
efficacy
Stage 2: supplemental item testing, final item selection
Stage 2 patient interviews
The patient population inclusion/exclusion criteria, cog-
nitive debriefing interview methods, and analysis were
the same as for Stage 1 interviews.
Final supplemental item selection
Cognitive debriefing interviews were followed by an
interview with a clinical expert to review patient feed-
back and provide clinical insight on items that may
assess treatment benefit. Items were further discussed
with the drug development team to determine whether
the drug’s mechanism of action was likely to impact the
identified symptom and impact concepts. The final sup-
plemental items were selected based on evidence generated
Fig. 1 Mixed methods study process
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from patient interviews, the item descriptive statistics, and
clinical consultation.
Results
Stage 1: supplemental item identification
Literature review
Of the 84 studies identified in the initial database search,
only four of these proved to be qualitative articles
focused on the patient-reported experience of MDS or
AML. A total of 31 symptom concepts and 48 impact
concepts were identified from these studies. These
concepts were organized into draft hypothesized concep-
tualizations of treatment benefit for MDS and AML
patients comprising seven symptom domains and eight
impact domains. In Table 2 below, there are 30 symptom
concepts from the literature; muscle pain and muscle
soreness were collapsed from two separate concepts into
one (muscle pain/soreness). In Table 3 below, there are
43 impact concepts from the literature; five concepts
(problems walking in certain places, problems walking
long distances, problems walking on unleveled ground,
problems walking up and down stairs, and unsteady gait)
were collapsed into one concept (walking).
Clinical consultation
Clinicians reviewed the symptoms and impacts extracted
from the literature, highlighted the importance of
fatigue, shortness of breath, and the significant impact
on patient functioning, and identified additional con-
cepts not found in the literature search. All clinician
feedback was considered and incorporated into the
emerging symptom and impact conceptualizations,
which retained the original hypothesized domains.
Stage 1 patient interviews
Study sample The Stage 1 study sample included 14
patients; Stage 2 included 18 patients. All enrolled
patients completed the study (see Table 1).
Concept elicitation results Forty-seven disease and
treatment-related symptom concepts and 53 disease and
treatment-related impact concepts spontaneously arose
from patient interviews. All patients experienced fatigue,
which was reported by patients as one of the most
bothersome symptoms. Patients reported feeling easily
fatigued, tired, low energy, and exhaustion. Most pa-
tients also reported experiencing shortness of breath,
weakness, pain, nausea, bruising, constipation, and dizzi-
ness. Disease-related symptoms and side effects of treat-
ments were also reported to have substantial impact on
patients’ HRQOL; including difficulty performing daily
activities, walking, doing leisure activities, and participat-
ing in activities that could expose them to infection
(such as eating out, traveling, and caring for others).
Concepts from these 14 interviews were analyzed for
saturation. The four new codes that emerged during the
final quantile did not provide additional information to
inform the conceptual framework, therefore saturation
was considered achieved. The symptom and impact
conceptualizations were updated with the additional
symptom and impact data and retained the original hy-
pothesized domains (see Tables 2 and 3).
EORTC QLQ-C30 cognitive debriefing and item
endorsement results Patients generally found the items
of the EORTC QLQ-C30 acceptable and clear. Overall,
the endorsement frequencies showed a good spread, in-
dicating that most of the items were relevant to this
sample (see Table 4). Some items showed high floor
effects, indicating fewer problems with these symptoms/
functions in this population; examples included nausea,
vomiting, difficulty concentrating, and needing help
eating, dressing, and washing.
Gap analysis and supplemental item identification
Fifty-four unique symptom concepts and 72 unique
impact concepts were identified; 18/54 symptoms and
30/72 impacts arose exclusively from patient interviews.
The consolidated frameworks of symptoms and impacts
are illustrated in Tables 2 and 3.
We compared symptom and impact concepts elicited
from all sources to the items of the EORTC QLQ-C30
and identified conceptual gaps of the instrument in this
context of use. Areas for possible measurement im-
provement due to gaps in the conceptual coverage were
highlighted and 13 supplemental items from the EORTC
Item Library were selected: bone pain [31], weakness
(lack of physical strength, muscle weakness), fatigue
(mobility), easily fatigued, lack of energy [32], bruising
[14], dizziness/light headedness [28], shortness of breath
[14], dyspnea on exertion [31], traveling to medical ap-
pointments/general travel [29], household chores [33],
shopping/running errands [32]. Of note, one key concept
(nosebleeds) met the item inclusion criteria, but it was
not in the EORTC Item Library at the time of supple-
mental item selection and thus not included. An item
around nosebleeds has since been added to the EORTC
Item library.
Stage 2: supplemental item testing, final item selection
Stage 2 patient interviews
Cognitive debriefing results Most supplemental items
were relevant and generally well understood. Some pa-
tients attributed the “bone pain” item to age, injury, or
arthritis rather than to their disease or treatments.
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Several patients found the “travel limitations” item un-
clear, as they were unsure what type of travel to consider
(e.g., car travel vs. air travel, long vs. short journey).
Finally, patients identified some issues with EORTC sup-
plemental items such as “difficulty with stairs or getting
out of a chair due to weakness,” which target more than
one concept. For instance, some patients had difficulty
with stairs but no trouble getting out of a chair, which
made selecting a response option difficult.
Item-level endorsement frequency results All but four
of the EORTC QLQ-C30 items met the WHOQOL cri-
teria and showed satisfactory endorsement frequencies
with a good spread of responses, indicating that these
items are generally relevant and well-targeted to this
patient sample (Table 5). All 13 supplemental items met
the item level criteria, suggesting good targeting and
relevance for this sample.
Patterns of endorsement frequencies suggested patients
appeared to have more problems with strenuous activities
Table 1 Patient demographic and clinical characteristics
Sample characteristics Stage 1
(n = 14)
Stage 2
(n = 18)
Recruitment source
MDS Foundation 6 (43%) 11 (61%)
Physician referral 8 (57%) 7 (39%)
Diagnosis type
Higher-risk MDS 11 (79%) 14 (78%)
Low-blast count AML 1 (7%) 1 (6%)
CMML 2 (14%) 3 (17%)
Age, years
Mean (SD) 68.8 (±8.48) 68.1 (±10.1)
Minimum 54 50
Maximum 83 83
Gender
Female 9 (64%) 10 (56%)
Male 5 (36%) 8 (44%)
Education level
Post-graduate degree 5 (36%) 5 (28%)
Undergraduate degree 1 (7%) 1 (6%)
Some college 3 (21%) 3 (17%)
Trade/technical degree 0 (0%) 1 (6%)
High school/General Educational
Development equivalent
4 (29%) 6 (33%)
Some high school or less 1 (7%) 2 (12%)
Employment status
Retired 8 (57%) 10 (56%)
Part-time 3 (21%) 3 (17%)
Full-time 2 (14%) 1 (6%)
Disability 1 (7%) 3 (17%)
Not employed 0 (0%) 1 (6%)
Eastern Cooperative Oncology Group status
Clinician-
reported
0 – fully active 1 (7%) 1 (6%)
1 – restricted in physically
strenuous activity
7 (50%) 6 (33%)
Patient-
reported
1 – difficulty with physically
strenuous activity
1 (17%) 5 (28%)
2 – able to walk and care for
self, restricted in work activities
5 (36%) 6 (33%)
Classification (clinician-reported only) n = 8 n = 7
FAB- Refractory anemia 1 (13%) 1 (14%)
WHO-RAEB1 3 (38%) 2 (29%)
WHO-RAEB2 1 (13%) 1 (14%)
FAB- Refractory anemia, WHO RAEB1 2 (25%) 2 (29%)
FAB-CMML and WHO-CMML1 1 (12%) 1 (14%)
Prognostic risk categoryb (MDS only) n = 11 n = 10
Very high 4 (36%) 3 (30%)
High 3 (27%) 3 (30%)
Table 1 Patient demographic and clinical characteristics
(Continued)
Sample characteristics Stage 1
(n = 14)
Stage 2
(n = 18)
Intermediate 2 (18%) 2 (20%)
Unknown 2 (18%) 2 (20%)
Hemoglobin level
7.0–9.9 6 (43%) 9 (50%)
10.0–11.9 6 (43%) 6 (33%)
12.0–13.0 2 (14%) 3 (17%)
% myeloblasts in bone marrow
(patient-reported only)
n = 6 n = 10
< 1% 1 (17%) 1 (10%)
1–9.9% 3 (50%) 5 (50%)
10–11% 1 (17%) 1 (10%)
Missing data 1 (17%) 3 (30%)
Treatmenta
Azacitidine 9 (64%) 12 (67%)
Decitabine 2 (14%) 2 (11%)
G-CSF; copper gluconate; ondansetron;
sulfamethoxazole / trimethoprim;
levofloxacin; valacyclovir; acetaminophen/
hydrocodone; oxycodone;
prochlorperazine
1 (7%) each 1 (6%) each
Unidentified clinical trial study drug 0 (0%) 1 (6%)
No treatment 0 (0%) 1 (6%)
Abbreviations: AML Acute myeloid leukemia, CMML Chronic myelomonocytic
leukemia, FAB French American British, G-CSF Granulocyte-colony stimulating
factor, MDS Myelodysplastic syndromes, RAEB Refractory anemia with excess
blasts, SD Standard deviation, WHO World health organization
aNot mutually exclusive, missing treatment data for 1 patient
bPer International Prognostic Scoring System-Revised [30]
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and fewer problems with staying in bed/chair, vomit-
ing, concentrating, feeling tense, depressed, remem-
bering things, travel limitations, and overall health
and quality of life items. Endorsement frequencies of
0% at the two ends of the scale for these items
could further inform item relevance and indicate
fewer/more problems associated with the symptoms/
functions of these items compared to the rest. It is
worth noting that test design issues were detected
for one EORTC QLQ-C30 item (need help eating,
dressing, washing) and one supplemental item (diffi-
culty with stairs or getting up from chair), which
target more than one concept.
Selection of final supplemental items Cognitive
debriefing of the 13 proposed supplemental items indi-
cated important comprehension issues with two items:
bone pain and travel limitations. No concerns were
raised for any of the items based on the quantitative ana-
lyses. A clinical expert reviewed Stage 2 patient data and
identified four supplemental items (bone pain, bruising,
Table 2 Consolidated symptom conceptualization of patient
experience with MDS, AML and CMML
Disease- and Treatment-Related Symptoms of Higher-Risk MDS,
Low-Blast Count AML, and CMML
PT LIT CLINa
Gastrointestinal
Nausea ✓ ✓ ✓
Constipation ✓ ✓ ✓
Vomiting ✓ ✓
Diarrhea ✓ ✓
Distension ✓
Feeling full after eating little food ✓
Bloating ✓
Loss of appetite ✓
Fatigue
Weakness ✓ ✓ ✓
Easily fatigued ✓ ✓ ✓
Tiredness ✓ ✓ ✓
Low Energy ✓ ✓ ✓
Exhausted ✓
Heaviness (arms/legs) ✓ ✓
Sluggish ✓ ✓ ✓
Worn out ✓ ✓
Pain
Bone pain ✓ ✓
Muscle pain/soreness ✓ ✓ ✓
Headache ✓ ✓ ✓
Cramps ✓
Chemical burn ✓
Bleeding
Bleeding ✓ ✓ ✓
Bruising ✓ ✓
Petechiae ✓
Cognitive function
Difficulty concentrating ✓ ✓ ✓
Memory loss ✓
Confusion ✓
Sensory
Dry throat/mouth ✓ ✓
Tastelessness ✓
Taste changes ✓
Dry lips ✓
Ringing in the ears ✓
Numbness ✓ ✓
Cold hands/feet ✓
Feeling cold ✓
Itchy skin ✓
Table 2 Consolidated symptom conceptualization of patient
experience with MDS, AML and CMML (Continued)
Disease- and Treatment-Related Symptoms of Higher-Risk MDS,
Low-Blast Count AML, and CMML
PT LIT CLINa
Other
Shortness of breath ✓ ✓ ✓
Rash ✓ ✓
Infection (e.g., cough, chest congestion,
sputum production, dysuria)
✓ ✓
Dizziness ✓ ✓
Lightheaded ✓
Dyspnea on exertion ✓ ✓ ✓
High fever/chills ✓ ✓ ✓
Paleness ✓ ✓
Weight gain/loss ✓ ✓
Hair loss ✓ ✓
Vertigo ✓ ✓
Anorexia ✓ ✓
Cardiac issues ✓ ✓
Eyes tearing ✓
Skin peeling ✓
Skin tearing ✓
Swelling (lymph nodes) ✓
Dysphagia (difficulty swallowing) ✓
✓ indicates concept explicitly endorsed by referenced source
Abbreviations: PT Patient-reported concept, LIT Literature-based concept, CLIN
Clinician-supported concept
aClinicians reviewed and endorsed all literature-based concepts in
this framework
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Table 3 Consolidated impact conceptualization of patient
experience with MDS, AML and CMML
Health-Related Quality of Life Impacts of Higher-Risk MDS, Low-Blast
Count AML, and CMML
PT LIT CLINa
Mobility
Walking (e.g., problems walking
long distances, walking in certain
places, walking on unleveled
ground, walking on stairs,
unsteady gait)
✓ ✓ ✓
Stay in bed/chair ✓
Inability to move quickly (move slowly) ✓ ✓
Exercising ✓ ✓
Loss of coordination ✓
Rising from sitting ✓
Bending down ✓
Lack of balance ✓
Falling ✓
Standing ✓
Sleep
Insomnia ✓ ✓
Feeling sleepy ✓ ✓ ✓
Waking from sleep ✓ ✓
Sleep disturbances ✓ ✓
Work/Finances
Inability to carry out jobs ✓ ✓ ✓
Time lost from work ✓ ✓
Loss of employment ✓ ✓
Treatment costs ✓ ✓
Leisure
Recreational activities (e.g., bowling,
golfing, sporting events, fishing,
bird watching)
✓ ✓ ✓
Yardwork ✓
Limited air travel ✓ ✓
Watching television ✓
Watching movies/theater ✓
Taking extending vacations ✓ ✓
Arts and crafts ✓
Reading ✓
Writing ✓
Board games ✓
Diet and nutrition
Avoid dining out ✓
Avoid certain foods ✓
Psychological Impact
Treatment burden ✓
Low motivation ✓ ✓
Anxiety ✓ ✓
Worry ✓ ✓
Table 3 Consolidated impact conceptualization of patient
experience with MDS, AML and CMML (Continued)
Health-Related Quality of Life Impacts of Higher-Risk MDS, Low-Blast
Count AML, and CMML
PT LIT CLINa
Feeling discouraged ✓
Sadness ✓
Increased sense of awareness ✓ ✓
Guilt ✓
Depression ✓ ✓
Anger ✓ ✓
Frustration ✓ ✓
Irritability ✓
Loss of confidence ✓
Distress ✓
Feeling overwhelmed ✓
Stress ✓
Strengthening pre-existing faith ✓
New-found appreciation ✓
Struggle to find meaning in one’s illness ✓
Feeling uncertainty ✓
Bored ✓
Fear ✓ ✓
Social limitation
Isolation ✓ ✓ ✓
Wearing protective masks ✓ ✓
Exposure to/ interaction with children/ grandchildren ✓ ✓ ✓
Relationships ✓ ✓ ✓
Sex life ✓
Attendance at parties/celebrations ✓
Restricting visits from sick people ✓ ✓ ✓
Attending church ✓
Inability to maintain roles ✓ ✓
Activities and daily living
Shopping ✓
Childcare ✓ ✓
Household chores ✓ ✓ ✓
Caring for others ✓ ✓
Driving ✓
Grooming ✓
Showering/bathing ✓
Need supervision bathing ✓
Getting dressed ✓
Traveling to hospital ✓
✓ indicates concept explicitly endorsed by referenced source
Abbreviations: PT Patient-reported concept, LIT Literature-based concept,
CLIN Clinician-supported concept
aClinicians reviewed and endorsed all literature-based concepts in
this framework
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dizzy, and travel limitations) as less relevant when con-
sidering overall treatment benefit. Finally, consult-
ation with clinical experts and the drug development
team indicated that bruising may be associated with
treatment administration and therefore unlikely to
demonstrate treatment benefit in the clinical trial
context as all treatments and supportive care are ad-
ministered intravenously or via injections. Based
upon all the amassed input, three items (bone pain,
bruising, and travel limitations) were removed from
the supplemental item set leaving seven symptom
and three impact items (see supplemental materials).
Discussion
Given their complexities, rare disease clinical trials re-
quire PRO strategies that are flexible and innovative [4].
In our study, integrating data from different sources
through a mixed methods framework provided a prag-
matic and efficient approach to maximizing the applic-
ability of a legacy PRO instrument in a new context of
use [15]. The initial literature review, consultation with
clinicians, and interviews with patients led to an
improved conceptual framework, thus enabling us to se-
lect and test supplemental items from the EORTC Item
Library relevant to the HR MDS, LB AML and CMML
Table 4 EORTC QLQ-C30: Item-level endorsement frequencies (n = 14) from Stage 1
EORTC QLQ-C30
Not at all % A little % Quite a bit % Very much %
1 Strenuous activities 7.1 28.6 42.9 21.4
2 Long walk 7.1 14.3 42.9 35.7
3 Short walk 35.7 50.0 14.3 0.0
4 Stay in bed/chair 57.1 21.4 14.3 7.1
5 Need help eating, dressing, washinga 85.7 14.3 0.0a 0.0a
6 Limited work or daily activities 14.3 57.1 28.6 0.0
7 Hobbies 35.7 28.6 14.3 21.4
8 Shortness of breath 14.3 64.3 14.3 7.1
9 Pain 50.0 21.4 21.4 7.1
10 Need to rest 7.1 35.7 35.7 21.4
11 Trouble sleeping 42.9 35.7 7.1 14.3
12 Feeling weak 7.1 57.1 14.3 21.4
13 Lack of appetite 28.6 50.0 42.9 7.1
14 Nauseaa 50.0 42.9 7.1a 0.0a
15 Vomitinga 71.4 28.6 0.0a 0.0a
16 Constipation 28.6 28.6 28.6 14.3
17 Diarrheaa 71.4 21.4 0.0a 7.1a
18 Tiredness 0.0 50.0 28.6 21.4
19 Pain interfere daily activities 42.9 28.6 14.3 14.3
20 Difficulty concentrating 50.0 35.7 14.3 0.0
21 Feeling tense 35.7 50.0 14.3 0.0
22 Worry 14.3 57.1 21.4 7.1
23 Irritable mood 14.3 71.4 14.3 0.0
24 Depressed mood 42.9 42.9 7.1 7.1
25 Remembering things 42.9 35.7 21.4 0.0
26 Family life 35.7 28.6 21.4 14.3
27 Social activities 14.3 28.6 50.0 7.1
28 Financial difficulties 57.1 28.6 7.1 7.1
1 Very poor % 2% 3% 4% 5% 6% 7 Excellent %
29 Overall health 0.0 7.1 14.3 14.3 35.7 28.6 0.0
30 Overall quality of life 0.0 0.0 28.6 21.4 21.4 14.3 14.3
aItem falls short of the WHOQOL criteria
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Table 5 EORTC QLQ-C30 and supplemental items: Item-level endorsement frequencies (n = 18) from Stage 2
EORTC QLQ-C30
Not at all % A little % Quite a bit % Very much %
1 Strenuous activities 0.0 38.9 44.4 16.7
2 Long walk 0.0 22.2 33.3 44.4
3 Short walk 27.8 55.6 11.1 5.6
4 Stay in bed/chair 27.8 44.4 27.8 0.0
5 Need help eating, dressing, washinga 77.8 16.7 5.6a 0.0a
6 Limited work or daily activities 11.1 44.4 33.3 11.1
7 Hobbies 33.3 33.3 27.8 5.6
8 Short of breath 27.8 38.9 22.2 11.1
9 Pain 27.8 16.7 27.8 27.8
10 Need to rest 16.7 27.8 33.3 22.2
11 Trouble sleeping 33.3 22.2 27.8 16.7
12 Felt weak 16.7 38.9 16.7 27.8
13 Lacked appetite 61.1 16.7 16.7 5.6
14 Nauseated 77.8 5.6 11.1 5.6
15 Vomiteda 88.9a 5.6a 5.6a 0.0a
16 Constipated 22.2 33.3 33.3 11.1
17 Diarrhea 66.7 22.2 5.6 5.6
18 Tired 11.1 44.4 22.2 22.2
19 Pain interfere daily activities 33.3 27.8 16.7 22.2
20 Difficulty concentrating 50.0 27.8 22.2 0.0
21 Feel tensea 33.3 61.1 5.6a 0.0a
22 Worry 22.2 61.1 5.6 11.1
23 Irritable 22.2 61.1 11.1 5.6
24 Depresseda 33.3 61.1 0.0a 5.6a
25 Remembering things 44.4 44.4 11.1 0.0
26 Family life 33.3 44.4 11.1 11.1
27 Social activities 22.2 27.8 33.3 16.7
28 Financial difficulties 38.9 38.9 16.7 5.6
1 Very poor % 2% 3% 4% 5% 6% 7 Excellent %
29 Overall health 0.0 0.0 33.3 27.8 22.2 11.1 5.6
30 Overall quality of life 0.0 0.0 16.7 27.8 22.2 11.1 22.2
Supplemental items
Not at all % A little % Quite a bit % Very much %
1 Bone aches or pains 38.9 27.8 16.7 16.7
2 Arms/legs weak 27.8 16.7 33.3 22.2
3 Slowed down 11.1 27.8 44.4 16.7
4 Easily tired 11.1 33.3 38.9 16.7
5 Lacked energy 16.7 22.2 44.4 16.7
6 Bruise 44.4 38.9 11.1 5.6
7 Dizzy 66.7 22.2 0.0 11.1
8 Exertion shortness of breath 22.2 22.2 44.4 11.1
9 Stop for breath when walking 33.3 27.8 27.8 11.1
10 Stairs/getting up from chair 27.8 27.8 27.8 16.7
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context that addressed concepts that were not captured
by the EORTC QLQ-C30. We believe this study illus-
trates a promising method for selecting supplemental
items from the EORTC Item Library to capture specific
concepts not covered in the EORTC QLQ-C30 for use
in therapeutic trials in different cancer contexts.
Our work began with this same emphasis on under-
standing the patients’ perspectives of the symptoms and
impacts of their disease. The literature review highlighted
the dearth of patient-focused, qualitative research in the
targeted conditions. Our work with patients contributes to
the literature on the patient experience of these diseases,
particularly as 18 of the symptoms and 30 of the impacts
identified from patient interviews arose exclusively from
patients and were not identified in earlier research. This
information was combined with perspectives from health
care professionals, researchers, and all other patient-based
evidence available to illustrate relationships among the
most important signs, symptoms, concerns, and disease
impacts. In the rare disease context, sample sizes will
always be small, so it is imperative to pay careful attention
to the patient voice. In these situations, combining fidelity
to the patient voice with small scale quantitative analyses
and re-testing iterations with patients is a pragmatic
approach to instrument choice and development.
A key strength of this research is its broad evidence
base and incorporation of findings from all stakeholders,
which, particularly in the rare disease context, can lead
to a consensus on the best way to collect and report key
outcomes [4], while still placing the patient’s voice at the
center of measurement. Consultation with clinicians and
drug development researchers at several stages of the
project provided a practical perspective on which
patient-identified symptoms and impacts were likely to
show treatment benefit in the specific clinical trial under
consideration – this approach can be generalized to
other concepts important to patients in this and other
contexts of use.
For example, in a previous project that aimed to im-
prove targeting of the 12-item Multiple Sclerosis Walk-
ing Scale for higher functioning multiple sclerosis
patients, a Gait Module was developed through a
multi-phase mixed method study design that included
concept elicitation, item generation, cognitive debriefing,
and Rasch analysis [34]. Supplemental items were also
“bolted-on” to the ABILHAND, a PRO instrument de-
signed to assess manual ability, by employing a mixed
methods approach to enhance its sensitivity to change
and reduce ceiling effects [35]. Both studies were based
on a thorough understanding of the patients’ perspec-
tives on their disease and a thoughtful conceptualization
of treatment benefit using information from both clinical
experts and published literature as the foundation for
selecting items to expand the measurement range of the
existing instruments. We hope these sorts of studies will
be the beginning of a growing body of research.
Limitations of this work should be acknowledged. The
initial conceptualization of treatment benefit did not in-
clude CMML patients; however, this patient perspective
was addressed during the patient interview phases of the
study. As is typical in rare disease studies, the sample
size was small (though representative of the patients with
these conditions) and some patients were recruited
through support/advocacy groups; both of these factors
could potentially limit the generalizability of our findings.
Furthermore, only about half of the patients from each
stage had a clinically confirmed diagnosis. Demographic
questions gathered information about patient character-
istics that helped provide supporting evidence of their
diagnosis; additionally, a small-scale analysis indicated
no significant differences between data collected from
patients with confirmed vs. non-confirmed diagnoses.
Finally, few patients were managed with supportive care
only, which offered challenges in terms of understanding
the burden of disease pertaining to symptoms and im-
pacts versus those related to treatment, though this was
carefully considered in our literature review and clinician
consultations. Given the limitations around this small-
scale mixed methods analysis, additional evaluations of
the core QLQ-C30 plus supplemental items should be
performed to ensure that these are fit-for-purpose PRO
measures in HR MDS, LB count AML, and CMML.
This study is potentially of interest to any clinical in-
vestigator working in drug development and patient-cen-
tered outcomes, as we have outlined a pragmatic
approach to PRO instrument modification that includes
the patient voice, as well as a strong mixed methods
approach. This practice aligns with emerging best prac-
tices within the area of rare disease [4, 10]. In addition,
this revised instrument may be beneficial for patients,
health care practitioners, and regulatory agencies who
either make or are affected by decisions regarding the
treatment of HR MDS, CMML, and LB count AML. It
is important to note that the items selected from the
Table 5 EORTC QLQ-C30 and supplemental items: Item-level endorsement frequencies (n = 18) from Stage 2 (Continued)
11 Travel ability limitations 66.7 16.7 16.7 0.0
12 Heavy housework 11.1 16.7 27.8 44.4
13 Shopping exhausting 27.8 11.1 33.3 27.8
aItem falls short of the WHOQOL criteria
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EORTC Item Library are not to be used as a single tool
or new EORTC measure, but to be used in conjunction
with the EORTC QLQ-C30. Further research is planned,
as the EORTC QLQ-C30 and supplemental items will be
tested in larger clinically-defined samples of patients
with MDS, AML and CMML to evaluate their combined
measurement properties in this context of use.
Conclusion
The current study is an example of how incorporating
the patient voice early in PRO instrument development
and using a conceptually-driven approach to select items
to increase conceptual coverage can lead to fit-for-pur-
pose PRO instrument for clinical trials. We have used
mixed methods research to select the most appropriate
supplemental items from the EORTC Item Library to in-
crease its conceptual coverage and its appropriateness
for use in the specific population of patients with HR
MDS, LB count AML and CMML. Ongoing psychomet-
ric evaluations in this patient population will shed fur-
ther light on the appropriateness of both the original
EORTC QLQ-C30 and enhanced item sets in this
specific patient population.
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